Stalevo is a prescription-only medication used in the management of Parkinson’s disease. It combines three active ingredients-levodopa, carbidopa and entacapone-into a single pill. The formulation is available in a fixed-dose combination of 25 mg levodopa / 100 mg carbidopa / 200 mg entacapone per tablet. In Hong Kong, Stalevo is regulated by the Department of Health and may be prescribed by neurologists or other qualified physicians.
Together, the three components provide more consistent dopamine levels, which reduces “off” periods (times when symptoms return) and improves overall motor function.
Stalevo is approved for use in adult patients with Parkinson’s disease who experience motor fluctuations while on a stable levodopa regimen. It is indicated as an adjunct therapy to:
The medication is not approved for other neurological or movement disorders.
Current peer-reviewed literature provides limited support for off-label applications of the levodopa/carbidopa/entacapone combination. Small case series have explored its use in atypical parkinsonian syndromes, but robust clinical trials are lacking. Off-label use requires close medical supervision and individualized risk assessment.
If you fall into any of these categories, discuss alternatives with your healthcare provider.
These effects are often transient and may improve with dose titration.
If you experience sudden fever, severe muscle rigidity, or uncontrolled tremor, seek immediate medical attention.
Patients should provide a complete medication and supplement list to their prescriber before initiating Stalevo.
Regular follow-up with a neurologist ensures optimal dose adjustments and early detection of adverse effects.
This article provides educational information about Stalevo and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Stalevo may be combined with dopamine agonists, anticholinergics, or MAO-B inhibitors when prescribed by a neurologist. The prescriber will evaluate potential additive effects and adjust doses accordingly.
A skin rash could indicate an allergic reaction. Discontinue the medication and seek medical evaluation promptly; a healthcare provider may prescribe an alternative regimen.
High-protein meals can reduce levodopa absorption. Many clinicians recommend spreading protein intake throughout the day or limiting large protein meals around dosing times to maintain consistent drug levels.
Stalevo offers a single-tablet convenience, reducing pill burden and potential dosing errors. The pharmacologic effects are equivalent because each tablet contains the same fixed ratio of the three active ingredients.
Entacapone is metabolised in the liver, so clinicians may start with a lower dose and monitor liver enzymes. Mild hepatic impairment does not automatically preclude use, but careful supervision is required.
Symptoms may include severe nausea, vomiting, confusion, irregular heartbeat, or difficulty breathing. Immediate medical attention is necessary; treatment focuses on supportive care.
Stalevo is a prescription medication. Carry it in its original packaging with a copy of the prescription and a doctor’s note if possible. Check the destination country’s regulations regarding controlled substances.
Some sleep aids, such as antihistamines, can increase sedation and dizziness when combined with Stalevo. Discuss any OTC medications with your prescriber before use.
Patients often experience a reduction in “off” time within a few days to two weeks, but the full therapeutic effect may require several weeks of dose optimisation.
